Arcadia appoints CEO Thomas Schaefer to board as Class I director, filling Jacot vacancy

Arcadia Biosciences, Inc.

Thomas J. Schaefer, current president and CEO, appointed Class I director effective August 1, 2024.
Appointment fills board vacancy created by Stanley Jacot's resignation on July 2, 2024.
Schaefer has served as CEO since July 2022 and as CFO since January 2023; no compensation change disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Thomas J. Schaefer

Class I Director

RKDA · Arcadia Biosciences, Inc.

Effective: 2024-08-01
Filed: August 7, 2024, 7:59 PM ET

On August 1, 2024, the board of directors (the “Board”) of Arcadia Biosciences, Inc. (“Arcadia” or the “Company”) appointed Thomas J. Schaefer, Arcadia’s current president and chief executive officer, to serve as a Class I director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas J. Schaefer was appointed as Class I Director at Arcadia Biosciences, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On August 1, 2024, the board of directors (the “Board”) of Arcadia Biosciences, Inc. (“Arcadia” or the “Company”) appointed Thomas J. Schaefer, Arcadia’s current president and chief executive officer, to serve as a Class I director of the Company.

View on SEC.gov

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-092432

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.